BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang H, Xu T, Huang Q, Jin W, Chen J. Immunotherapy for Malignant Glioma: Current Status and Future Directions. Trends Pharmacol Sci. 2020;41:123-138. [PMID: 31973881 DOI: 10.1016/j.tips.2019.12.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 53] [Article Influence: 11.5] [Reference Citation Analysis]
Number Citing Articles
1 Li S, Li J, Fan Y, Huang T, Zhou Y, Qiu R, Zhang Q, Fan H. The mechanism of formononetin/calycosin compound optimizing the effects of temozolomide on C6 malignant glioma based on metabolomics and network pharmacology. Biomedicine & Pharmacotherapy 2022;153:113418. [DOI: 10.1016/j.biopha.2022.113418] [Reference Citation Analysis]
2 Shi W, Ding W, Zhao Z, Wang R, Wang F, Tang Y, Zhu J, Su C, Zhao X, Liu L. Peroxidase is a novel potential marker in glioblastoma through bioinformatics method and experimental validation. Front Genet 2022;13:990344. [DOI: 10.3389/fgene.2022.990344] [Reference Citation Analysis]
3 Shi J, Yang N, Han M, Qiu C. Emerging roles of ferroptosis in glioma. Front Oncol 2022;12:993316. [DOI: 10.3389/fonc.2022.993316] [Reference Citation Analysis]
4 Zhu Z, Fang C, Xu H, Yuan L, Du Y, Ni Y, Xu Y, Shao A, Zhang A, Lou M. Anoikis resistance in diffuse glioma: The potential therapeutic targets in the future. Front Oncol 2022;12:976557. [DOI: 10.3389/fonc.2022.976557] [Reference Citation Analysis]
5 Yu Z, Yang H, Song K, Fu P, Shen J, Xu M, Xu H. Construction of an immune-related gene signature for the prognosis and diagnosis of glioblastoma multiforme. Front Oncol 2022;12:938679. [DOI: 10.3389/fonc.2022.938679] [Reference Citation Analysis]
6 Wang F, Zhao F, Zhang L, Xiong L, Mao Q, Liu Y, Qiu X, Wang X, Shui L, Chen X, Ren K, Shui P, Zhang Q, Deng Y, Li W, Xie X, Wu D, Li T, Lang J, Liu L, Chen H, Xu J, Bai S, Li Z, Yue Q, Chen N, Zhou B, Yi C, Wei Y, Fu Y, Luo Y, Gou Q, Liu L, Liu Y, Kang J, Wang J, Jing D, Zhang F, Yang X, Li X, Jiang T, Zhang Z, Zhou Y, Yi J. CDC6 is a prognostic biomarker and correlated with immune infiltrates in glioma. Mol Cancer 2022;21:153. [PMID: 35879762 DOI: 10.1186/s12943-022-01623-8] [Reference Citation Analysis]
7 Wang K, Wang J, Zhang J, Zhang A, Liu Y, Zhou J, Wang X, Zhang J. Ferroptosis in Glioma Immune Microenvironment: Opportunity and Challenge. Front Oncol 2022;12:917634. [PMID: 35832539 DOI: 10.3389/fonc.2022.917634] [Reference Citation Analysis]
8 Luo N, Fu M, Zhang Y, Li X, Zhu W, Yang F, Chen Z, Mei Q, Peng X, Shen L, Zhang Y, Li Q, Hu G. Prognostic Role of M6A-Associated Immune Genes and Cluster-Related Tumor Microenvironment Analysis: A Multi-Omics Practice in Stomach Adenocarcinoma. Front Cell Dev Biol 2022;10:935135. [DOI: 10.3389/fcell.2022.935135] [Reference Citation Analysis]
9 Ge MX, Shi YK, Liu D. Tripartite motif-containing 25 facilitates immunosuppression and inhibits apoptosis of glioma via activating NF-κB. Exp Biol Med (Maywood) 2022;:15353702221099460. [PMID: 35723030 DOI: 10.1177/15353702221099460] [Reference Citation Analysis]
10 Fernandes CFL, Coelho BP, Souza MCDS, Boccacino JM, Soares SR, Araújo JPA, Melo-Escobar MI, Lopes MH. Extracellular vesicles throughout development: A potential roadmap for emerging glioblastoma therapies. Semin Cell Dev Biol 2022:S1084-9521(22)00185-9. [PMID: 35697594 DOI: 10.1016/j.semcdb.2022.05.027] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Nie W, Chen J, Wang B, Gao X. Nonviral vector system for cancer immunogene therapy. MedComm – Biomaterials and Applications 2022;1:mba2.10. [DOI: 10.1002/mba2.10] [Reference Citation Analysis]
12 Liang M, Li J, Han L. Receptor-mediated cascade targeting strategies for the application to medical diagnoses and therapeutics of glioma. J Nanopart Res 2022;24. [DOI: 10.1007/s11051-022-05482-8] [Reference Citation Analysis]
13 Wei J, Wu D, Shao Y, Guo B, Jiang J, Chen J, Zhang J, Meng F, Zhong Z. ApoE-mediated systemic nanodelivery of granzyme B and CpG for enhanced glioma immunotherapy. J Control Release 2022:S0168-3659(22)00244-9. [PMID: 35513207 DOI: 10.1016/j.jconrel.2022.04.048] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Wei J, Wu D, Zhao S, Shao Y, Xia Y, Ni D, Qiu X, Zhang J, Chen J, Meng F, Zhong Z. Immunotherapy of Malignant Glioma by Noninvasive Administration of TLR9 Agonist CpG Nano-Immunoadjuvant. Adv Sci (Weinh) 2022;9:e2103689. [PMID: 35253404 DOI: 10.1002/advs.202103689] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
15 Liu Y, Yao R, Shi Y, Liu Y, Liu H, Liu J, Guan Y, Yao Y, Chen L. Identification of CD101 in Glioma: A Novel Prognostic Indicator Expressed on M2 Macrophages. Front Immunol 2022;13:845223. [PMID: 35350788 DOI: 10.3389/fimmu.2022.845223] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Agarwal P, Beale OM, Zhang X, Sandlesh P, Jaman E, Amankulor N. Machine Learning Identification of Immunotherapy Targets in Low-Grade Glioma using RNA Sequencing Expression Data. World Neurosurg 2022:S1878-8750(22)00416-8. [PMID: 35390499 DOI: 10.1016/j.wneu.2022.03.123] [Reference Citation Analysis]
17 Sun J, Li J, Lu Z, Chen L, Ma J. Analysis of the Mechanism of RAD18 in Glioma. Neuroimmunomodulation 2022;:1-11. [PMID: 35367987 DOI: 10.1159/000520761] [Reference Citation Analysis]
18 Yang S, Xie C, Guo T, Li H, Li N, Zhou S, Wang X, Xie C. Simvastatin Inhibits Tumor Growth and Migration by Mediating Caspase-1-dependent Pyroptosis in Glioblastoma Multiforme. World Neurosurg 2022:S1878-8750(22)00382-5. [PMID: 35342027 DOI: 10.1016/j.wneu.2022.03.089] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Chen Z, Wang X, Yan Z, Zhang M. Identification of tumor antigens and immune subtypes of glioma for mRNA vaccine development. Cancer Med 2022. [PMID: 35285582 DOI: 10.1002/cam4.4633] [Reference Citation Analysis]
20 Lu F, Shen SH, Wu S, Zheng P, Lin K, Liao J, Jiang X, Zeng G, Wei. Hypomethylation-induced prognostic marker zinc finger DHHC-type palmitoyltransferase 12 contributes to glioblastoma progression. Ann Transl Med 2022;10:334. [PMID: 35434031 DOI: 10.21037/atm-22-520] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Fang DD, Huang W, Cheng G, Liu XN, Liu SM, Hou BS, Mao J, Zhou H. Clinicopathological and Prognostic Significance of ABCC3 in Human Glioma. J Oncol 2021;2021:1827992. [PMID: 34976054 DOI: 10.1155/2021/1827992] [Reference Citation Analysis]
22 Wang X, Yu X, Wei K, Wang S, Liu Q, Wang Y, Li H, Huang C. Mesenchymal stem cells shuttling miR-503 via extracellular vesicles enhance glioma immune escape. OncoImmunology 2022;11:1965317. [DOI: 10.1080/2162402x.2021.1965317] [Reference Citation Analysis]
23 Li Y, Ma Y, Wu Z, Xie R, Zeng F, Cai H, Lui S, Song B, Chen L, Wu M. Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma. Front Immunol 2021;12:790674. [PMID: 34899760 DOI: 10.3389/fimmu.2021.790674] [Reference Citation Analysis]
24 Di W, Fan W, Wu F, Shi Z, Wang Z, Yu M, Zhai Y, Chang Y, Pan C, Li G, Kahlert UD, Zhang W. Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples. Cancer Sci 2021. [PMID: 34881489 DOI: 10.1111/cas.15236] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
25 Zhong A, Chen T, Zhou T, Zhang Z, Shi M. TPD52L2 Is a Prognostic Biomarker and Correlated With Immune Infiltration in Lung Adenocarcinoma. Front Pharmacol 2021;12:728420. [PMID: 34744715 DOI: 10.3389/fphar.2021.728420] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
26 Lin T, Cheng H, Liu D, Wen L, Kang J, Xu L, Shan C, Chen Z, Li H, Lai M, Zhou Z, Hong W, Hu Q, Li S, Zhou C, Geng J, Jin X. A Novel Six Autophagy-Related Genes Signature Associated With Outcomes and Immune Microenvironment in Lower-Grade Glioma. Front Genet 2021;12:698284. [PMID: 34721517 DOI: 10.3389/fgene.2021.698284] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
27 Ebrahimi AA, Ashoori H, Vahidian F, Mosleh IS, Kamian S. Long non-coding RNA panel as a molecular biomarker in glioma. J Egypt Natl Canc Inst 2021;33:31. [PMID: 34693506 DOI: 10.1186/s43046-021-00090-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
28 Wang C, Tu H, Yang L, Ma C, Hu J, Luo J, Wang H. FOXN3 inhibits cell proliferation and invasion via modulating the AKT/MDM2/p53 axis in human glioma. Aging (Albany NY) 2021;13:21587-98. [PMID: 34511432 DOI: 10.18632/aging.203499] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 He J, Zeng C, Long Y. Establishment of an Immune-Related Gene Signature for Risk Stratification for Patients with Glioma. Comput Math Methods Med 2021;2021:2191709. [PMID: 34497663 DOI: 10.1155/2021/2191709] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
30 Wang Z, Yao J, Guan Z, Wu H, Cheng H, Yan G, Tang R. pH-triggered small molecule nano-prodrugs emulsified from tryptamine-cinnamaldehyde twin drug for targeted synergistic glioma therapy. Colloids Surf B Biointerfaces 2021;207:112052. [PMID: 34416443 DOI: 10.1016/j.colsurfb.2021.112052] [Reference Citation Analysis]
31 Liu X, Zhang M, Zhu X, Wang Y, Lv K, Yang H. Loss of FAM60A attenuates cell proliferation in glioma via suppression of PI3K/Akt/mTOR signaling pathways. Transl Oncol 2021;14:101196. [PMID: 34388694 DOI: 10.1016/j.tranon.2021.101196] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
32 Zhang GL, Wang CF, Qian C, Ji YX, Wang YZ. Role and mechanism of neural stem cells of the subventricular zone in glioblastoma. World J Stem Cells 2021; 13(7): 877-893 [PMID: 34367482 DOI: 10.4252/wjsc.v13.i7.877] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
33 Tong N, He Z, Ma Y, Wang Z, Huang Z, Cao H, Xu L, Zou Y, Wang W, Yi C, Yin Z, Wang Q. Tumor Associated Macrophages, as the Dominant Immune Cells, Are an Indispensable Target for Immunologically Cold Tumor-Glioma Therapy? Front Cell Dev Biol 2021;9:706286. [PMID: 34368156 DOI: 10.3389/fcell.2021.706286] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
34 Zhang B, Yao J, Lian X, Liu B, Wang Y, Wang H, Wang J, Zhang M, Zhao Y, Zhu Y, Liu R, Gao Y. Role of RHOC in evaluating an adverse prognosis in patients with glioma and its potential prognostic value. Mol Clin Oncol 2021;15:171. [PMID: 34276990 DOI: 10.3892/mco.2021.2333] [Reference Citation Analysis]
35 Qiu X, Tian Y, Xu J, Jiang X, Liu Z, Qi X, Chang X, Zhao J, Huang J. Development and Validation of an Immune-Related Long Non-coding RNA Prognostic Model in Glioma. J Cancer 2021;12:4264-76. [PMID: 34093827 DOI: 10.7150/jca.53831] [Reference Citation Analysis]
36 Wan RJ, Peng W, Xia QX, Zhou HH, Mao XY. Ferroptosis-related gene signature predicts prognosis and immunotherapy in glioma. CNS Neurosci Ther 2021;27:973-86. [PMID: 33969928 DOI: 10.1111/cns.13654] [Cited by in Crossref: 1] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
37 Qu S, Liu J, Wang H. EVA1B to Evaluate the Tumor Immune Microenvironment and Clinical Prognosis in Glioma. Front Immunol 2021;12:648416. [PMID: 33889156 DOI: 10.3389/fimmu.2021.648416] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
38 Zhang H, Chen Z, Wang Z, Dai Z, Hu Z, Zhang X, Hu M, Liu Z, Cheng Q. Correlation Between APOBEC3B Expression and Clinical Characterization in Lower-Grade Gliomas. Front Oncol 2021;11:625838. [PMID: 33842328 DOI: 10.3389/fonc.2021.625838] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
39 Chen L, Qin D, Guo X, Wang Q, Li J. Putting Proteomics Into Immunotherapy for Glioblastoma. Front Immunol 2021;12:593255. [PMID: 33708196 DOI: 10.3389/fimmu.2021.593255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
40 Chen H, Li M, Guo Y, Zhong Y, He Z, Xu Y, Zou J. Immune response in glioma's microenvironment. Innov Surg Sci 2020;5:20190001. [PMID: 33511267 DOI: 10.1515/iss-2019-0001] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
41 Xie P, Wang Y, Wei D, Zhang L, Zhang B, Xiao H, Song H, Mao X. Nanoparticle-based drug delivery systems with platinum drugs for overcoming cancer drug resistance. J Mater Chem B 2021;9:5173-94. [PMID: 34116565 DOI: 10.1039/d1tb00753j] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
42 Tang T, Chang B, Zhang M, Sun T. Nanoprobe-mediated precise imaging and therapy of glioma. Nanoscale Horiz 2021;6:634-50. [PMID: 34110340 DOI: 10.1039/d1nh00182e] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
43 Zhang GL, Qian C, Zhang SZ, Tuo YH, Zeng BY, Ji YX, Wang YZ. Effect of conditioned medium from neural stem cells on glioma progression and its protein expression profile analysis. World J Stem Cells 2020; 12(11): 1396-1409 [PMID: 33312406 DOI: 10.4252/wjsc.v12.i11.1396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Zhang X, Zhou J, Gu Z, Zhang H, Gong Q, Luo K. Advances in nanomedicines for diagnosis of central nervous system disorders. Biomaterials 2021;269:120492. [PMID: 33153757 DOI: 10.1016/j.biomaterials.2020.120492] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
45 Hong L, Pliss AM, Zhan Y, Zheng W, Xia J, Liu L, Qu J, Prasad PN. Perfluoropolyether Nanoemulsion Encapsulating Chlorin e6 for Sonodynamic and Photodynamic Therapy of Hypoxic Tumor. Nanomaterials (Basel) 2020;10:E2058. [PMID: 33086490 DOI: 10.3390/nano10102058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
46 Lin JZ, Lin N. A risk signature of three autophagy-related genes for predicting lower grade glioma survival is associated with tumor immune microenvironment. Genomics 2021;113:767-77. [PMID: 33069830 DOI: 10.1016/j.ygeno.2020.10.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
47 Wawrzkiewicz-Jałowiecka A, Trybek P, Borys P, Dworakowska B, Machura Ł, Bednarczyk P. Differences in Gating Dynamics of BK Channels in Cellular and Mitochondrial Membranes from Human Glioblastoma Cells Unraveled by Short- and Long-Range Correlations Analysis. Cells 2020;9:E2305. [PMID: 33076484 DOI: 10.3390/cells9102305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
48 Yang M, Oh IY, Mahanty A, Jin WL, Yoo JS. Immunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives. Cancers (Basel) 2020;12:E2334. [PMID: 32824974 DOI: 10.3390/cancers12092334] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
49 Luo Y, Liu L, Li X, Shi Y. Avasimibe inhibits the proliferation, migration and invasion of glioma cells by suppressing linc00339. Biomed Pharmacother 2020;130:110508. [PMID: 32682982 DOI: 10.1016/j.biopha.2020.110508] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
50 Wang J, Xu S, Lv W, Shi F, Mei S, Shan A, Xu J, Yang Y. Uridine phosphorylase 1 is a novel immune-related target and predicts worse survival in brain glioma. Cancer Med 2020;9:5940-7. [PMID: 32583596 DOI: 10.1002/cam4.3251] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
51 Zhang M, Wang X, Chen X, Zhang Q, Hong J. Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma. Front Genet 2020;11:363. [PMID: 32351547 DOI: 10.3389/fgene.2020.00363] [Cited by in Crossref: 37] [Cited by in F6Publishing: 74] [Article Influence: 18.5] [Reference Citation Analysis]
52 Wawrzkiewicz-Jałowiecka A, Trybek P, Dworakowska B, Machura Ł. Multifractal Properties of BK Channel Currents in Human Glioblastoma Cells. J Phys Chem B 2020;124:2382-91. [PMID: 32129626 DOI: 10.1021/acs.jpcb.0c00397] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
53 Jin WL, Jin MZ, Tu YY. Organoids: A Platform Ready for Glioblastoma Precision Medicine? Trends Cancer 2020;6:265-7. [PMID: 32209439 DOI: 10.1016/j.trecan.2020.01.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]